Newsroom

SAN CARLOS, Califórnia--(BUSINESS WIRE)--A BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), empresa global de oncologia, apresentará hoje os pilares de sua crescente liderança global em oncologia durante sua apresentação na 44ª Conferência Anual de Saúde do J.P. Morgan, em San Francisco. John V. Oyler, cofundador, presidente do conselho e CEO da BeOne, destacará a liderança transformadora da empresa no tratamento das malignidades de células B. A apresentação trará o BRUKINSA®, líde...

SAN CARLOS, California--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), una empresa global de oncología, presentará hoy los ejes de su creciente posicionamiento internacional durante su participación en la 44.a Conferencia Anual de Salud de J.P. Morgan, que se celebra en San Francisco. John V. Oyler, cofundador, presidente y director ejecutivo de BeOne, destacará el impacto transformador de la empresa en el tratamiento de malignidades de células B. La presentación...

LONDON--(BUSINESS WIRE)--  As Agent Bank, please be advised of the following rate determined on: 1/13/2026 Issue ¦ Delamare Cards MTN Issuer plc Series 2023 - 2 Class - A1 GBP 250,000,000 FRN Due in Oct 2026     ISIN Number ¦ XS2697482573 ISIN Reference ¦ 269748257 Issue Nomin GBP ¦ 250000000 Period ¦ 12/19/2025 to 1/20/2026   Payment Date 1/20/2026 Number of Days ¦ 32 Rate ¦ 4.72883   Denomination GBP ¦ 1000   ¦ 250000000   ¦       Amount Payable per Denomination ¦ 4.15   ¦ 1036455.89   ¦    ...

LONDON--(BUSINESS WIRE)--  Re: Atlas Holdings 2025-1 Limited GBP 4,752,000.00 MATURING: 20-Jul-2062 ISIN: XS3037719138 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 22-Dec-2025 TO 20-Jan-2026 HAS BEEN FIXED AT 7.79 PCT DAY BASIS: ACTUAL/365(FIX) INTEREST PAYABLE VALUE 20-Jan-2026 WILL AMOUNT TO: GBP 29,413.40 PER GBP 4,752,000.00 DENOMINATION  ...

LONDON--(BUSINESS WIRE)--  Re: ATLAS FUNDING 2023 -1 PLC GBP 2,289,000.00 MATURING: 20-Jan-2061 ISIN: XS2601815645 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 22-Dec-2025 TO 20-Jan-2026 HAS BEEN FIXED AT 11.29 PCT DAY BASIS: ACTUAL/365(FIX) INTEREST PAYABLE VALUE 20-Jan-2026 WILL AMOUNT TO: GBP 7,715.11 PER GBP 860,051.06 DENOMINATION  ...

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired CoreWeave, Inc. (NASDAQ: CRWV) securities between March 28, 2025 and December 15, 2025. CoreWeave purports to be an artificial intelligence (“AI”) cloud computing company and self-described “Hyperscaler”, which it defines as “a cloud provider or technology company that is capable of delivering computing infrastructure and services at massive s...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Polaris Capital Management, LLC (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must b...

LONDON--(BUSINESS WIRE)--  Re: ATLAS FUNDING 2023 -1 PLC GBP 248,266,000.00 MATURING: 20-Jan-2061 ISIN: XS2601487619 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 22-Dec-2025 TO 20-Jan-2026 HAS BEEN FIXED AT 4.94 PCT DAY BASIS: ACTUAL/365(FIX) INTEREST PAYABLE VALUE 20-Jan-2026 WILL AMOUNT TO: GBP 839,778.04 PER GBP 213,938,271.04 DENOMINATION  ...

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), società oncologica globale, evidenzierà i pilastri della sua crescente leadership oncologica globale durante la sua presentazione oggi alla 44a Annual Healthcare Conference di J.P. Morgan a San Francisco. John V. Oyler, Cofondatore, Presidente e CEO di BeOne, evidenzierà la leadership innovativa della Società nella terapia dei tumori maligni a cellule B. La presentazione includerà BRUKINSA®, l'ini...

SAN CARLOS, Kalifornien--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), ein weltweit tätiges Onkologieunternehmen, wird im Rahmen seiner heutigen Präsentation auf der 44. jährlichen J.P. Morgan Healthcare Conference in San Francisco die Grundpfeiler seiner zunehmenden globalen Führungsrolle auf dem Gebiet der Onkologie vorstellen. John V. Oyler, Mitbegründer, Chairman und CEO von BeOne, wird die transformative Vorreiterrolle des Unternehmens bei der Behandlung vo...